Filing Flows › TriSalus Life Sciences (TLSI) › Q2 2025
TriSalus Life Sciences (TLSI) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
TriSalus Life Sciences (TLSI) reported revenue of $11.2M for the second quarter 2025 (Q2 2025), +52% from a year earlier and +22% from the quarter before. Operating margin was -65.4%, net loss $8.3M (73.9% of revenue).
TriSalus Life Sciences, Q2 2025: revenue $11.2M (+52% year over year), operating margin -65.4%, net loss $8.3M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.2M | +22% | +52% |
| Operating profit | −$7.3M | — | — |
| Net earnings | −$8.3M | — | — |
| Operating cash flow | −$7.3M | — | — |
What changed
Revenue was $11.2M in Q2 2025, up 52% year over year and up 22% from the previous quarter.
Gross margin was 83.9%, down 3.7 points from a year earlier. Operating costs exceeded revenue by $7.3M, an operating margin of -65.4%. Operating expenses grew 14% against revenue growth of 52%. The quarter ended with a net loss of $8.3M, narrower than the previous quarter's $10.4M loss.
Operating cash flow was −$7.3M. Non-cash charges added back $165K of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items used $1.1M. Capital expenditures of −$93K exceeded it, leaving free cash flow of −$7.2M.
Questions
What was TriSalus Life Sciences' revenue in the second quarter 2025?
TriSalus Life Sciences (TLSI) reported revenue of $11.2M for the second quarter 2025 (Q2 2025), +52% from a year earlier and +22% from the quarter before.
Was TriSalus Life Sciences profitable in the second quarter 2025?
Operating loss was $7.3M (-65.4% of revenue) and net loss $8.3M.